Benign anorectal disorders are often distressing, debilitating, and add significantly to the health care burden. This article summarizes a presentation on benign anorectal disorders by Damanpreet K. Grewal,...
A randomized Phase 3 U-ENDURE maintenance study compared the safety and efficacy of upadacitinib with placebo for the treatment of patients with moderate-to-severe Crohn disease.
The researchers discussed the use of risankizumab induction therapy and its ability to treat symptoms that greatly affect the lives of patients with Crohn disease. The research was presented at ACG 2022. ...
After 30 years, new guidelines and recommendations have been issued regarding metabolic and bariatric surgery, providing updated guidance for clinicians to follow.
According to a recent study, subcutaneous maintenance dosing of risankizumab at 52 weeks is effective and well-tolerated in patients with moderate-to-severe Crohn disease who had a delayed response to...
The researchers sought to compare the relative efficacy and safety of biologics and small molecule drugs for the treatment of patients with moderate-to-severe ulcerative colitis.
Researchers conducted a systematic review and meta-analysis to evaluate the efficacy and safety of fecal microbiota transplantation as a treatment for ulcerative colitis.
Researchers examined the presence of undiagnosed severe exocrine pancreatic insufficiency in individuals with irritable bowel syndrome plus diarrhea, as well as the associated symptoms and the impact of...
